PDCD1 and breast cancer: Unfortunately, most patients with BC, such as hormone-positive BCs, showed low response rates to the current immunotherapies such as PD-1 and PD-L1 inhibitors due to the paucity of infiltrating immune cells, which is called the “cold” immunological nature of BC (9).